A pilot study assessing the safety and response rate combination of SBRT followed by a high-dose IL-2 regimen in patients with metastatic melanoma and renal cell carcinoma showed complete response or partial response in 8 out of 12 patients (53). Here, IL2 is linked to hereditary clear cell renal cell carcinoma.